FDA
Biotech

AACR: Pazdur bemoans state of FDA, warns of political influence

Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump administration "for obvious reasons."
Darren Incorvaia Apr 18, 2026 4:00am
Money present

A new benchmark for biotech IPOs? Kailera raises $625M

Apr 17, 2026 4:42am
light bulb think theory idea bright dull lights out

Small pools, big ideas: Rare disease community reimagines trials

Apr 17, 2026 3:00am
merck

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

Apr 17, 2026 3:00pm
UCB sign

UCB strikes $1.15B deal for cell therapy biotech Neurona

Apr 17, 2026 1:55pm
Parachute over La Jolla California

Metsera sale architect swings to Structure—Chutes & Ladders

Apr 17, 2026 10:10am
More News

OpenAI launches biotech-specific AI model dubbed GPT-Rosalind

Apr 17, 2026 10:00am

Roivant’s CEO thinks China is a ‘red herring’

Apr 17, 2026 8:35am

RyghtAI launches clinical trial site search engine

Apr 16, 2026 2:35pm
Fierce Pharma

Anti-amyloid Alzheimer's drugs show 'trivial' effects: report

Apr 16, 2026 11:36am